BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E15.53 EPS (ttm)14.01 Insider Own0.20% Shs Outstand145.90M Perf Week4.04%
Market Cap31.74B Forward P/E13.75 EPS next Y15.83 Insider Trans0.00% Shs Float145.00M Perf Month1.08%
Income2.06B PEG- EPS next Q4.17 Inst Own87.30% Short Float1.44% Perf Quarter16.02%
Sales10.63B P/S2.98 EPS this Y-58.10% Inst Trans0.45% Short Ratio1.99 Perf Half Y-1.68%
Book/sh81.37 P/B2.67 EPS next Y-3.78% ROA8.50% Target Price234.25 Perf Year-36.04%
Cash/sh32.90 P/C6.61 EPS next 5Y-6.87% ROE18.50% 52W Range187.16 - 351.86 Perf YTD-9.31%
Dividend- P/FCF12.24 EPS past 5Y-9.30% ROI15.30% 52W High-38.15% Beta0.40
Dividend %- Quick Ratio1.70 Sales past 5Y-0.80% Gross Margin77.30% 52W Low16.27% ATR5.91
Employees9610 Current Ratio1.90 Sales Q/Q-6.70% Oper. Margin18.20% RSI (14)56.56 Volatility2.46% 2.85%
OptionableYes Debt/Eq0.61 EPS Q/Q142.20% Profit Margin19.40% Rel Volume0.45 Prev Close217.59
ShortableYes LT Debt/Eq0.53 EarningsJul 20 BMO Payout0.00% Avg Volume1.05M Price217.61
Recom2.40 SMA201.89% SMA504.34% SMA200-1.53% Volume252,323 Change0.01%
Apr-18-22Upgrade Wells Fargo Equal Weight → Overweight $235 → $265
Mar-08-22Downgrade Stifel Buy → Hold $304 → $223
Mar-03-22Upgrade RBC Capital Mkts Sector Perform → Outperform $227 → $248
Feb-04-22Reiterated Wolfe Research Peer Perform $244 → $217
Feb-04-22Reiterated Wells Fargo Equal Weight $284 → $235
Feb-04-22Reiterated Wedbush Neutral $195 → $185
Feb-04-22Reiterated Robert W. Baird Neutral $258 → $224
Feb-04-22Reiterated RBC Capital Mkts Sector Perform $225 → $227
Feb-04-22Reiterated Oppenheimer Outperform $350 → $285
Feb-04-22Reiterated Needham Buy $292 → $290
Feb-04-22Reiterated Morgan Stanley Overweight $360 → $330
Feb-04-22Reiterated Cowen Outperform $375 → $285
Feb-04-22Reiterated BofA Securities Neutral $245 → $230
Feb-04-22Reiterated Barclays Equal Weight $244 → $235
Feb-04-22Downgrade BMO Capital Markets Outperform → Market Perform $260 → $238
Jan-13-22Downgrade Guggenheim Buy → Neutral $290 → $202
Jan-12-22Downgrade Piper Sandler Overweight → Neutral $362 → $216
Dec-10-21Resumed Raymond James Mkt Perform
Dec-09-21Resumed Wells Fargo Equal Weight $250
Dec-06-21Initiated Goldman Neutral $271
Aug-10-22 08:14AM  
Aug-09-22 03:00PM  
10:53AM  
05:25AM  
Aug-05-22 08:00AM  
Aug-03-22 07:32PM  
Aug-01-22 10:08AM  
Jul-31-22 05:55AM  
Jul-29-22 10:40AM  
Jul-28-22 10:26AM  
09:44AM  
07:30AM  
Jul-27-22 11:15AM  
08:15AM  
Jul-26-22 10:21AM  
09:41AM  
08:26AM  
07:30AM  
Jul-25-22 12:00PM  
11:40AM  
Jul-22-22 01:13PM  
09:16AM  
09:04AM  
Jul-21-22 03:44PM  
10:40AM  
Jul-20-22 04:37PM  
04:21PM  
04:07PM  
04:03PM  
03:00PM  
01:52PM  
10:06AM  
09:14AM  
08:25AM  
08:05AM  
07:49AM  
07:45AM  
07:12AM  
07:09AM  
06:00AM  
04:01AM  
Jul-19-22 08:59AM  
Jul-18-22 11:10AM  
05:43AM  
Jul-17-22 01:00PM  
Jul-13-22 10:00AM  
Jul-08-22 11:09AM  
Jul-07-22 05:30AM  
Jul-06-22 10:00AM  
09:15AM  
09:04AM  
Jul-05-22 07:30PM  
07:30PM  
02:16PM  
Jun-29-22 04:00PM  
Jun-28-22 10:00AM  
Jun-27-22 06:15AM  
Jun-24-22 08:12AM  
Jun-23-22 10:32AM  
Jun-22-22 10:00AM  
09:00AM  
Jun-21-22 09:32AM  
06:37AM  
Jun-17-22 08:31AM  
Jun-16-22 09:52AM  
Jun-15-22 04:52PM  
07:30AM  
Jun-14-22 01:00PM  
12:00PM  
07:30AM  
Jun-09-22 11:15AM  
09:58AM  
Jun-08-22 10:33AM  
Jun-07-22 08:51AM  
Jun-06-22 07:30AM  
Jun-03-22 08:00AM  
05:20AM  
Jun-02-22 03:20PM  
11:31AM  
08:00AM  
Jun-01-22 04:10PM  
02:39PM  
09:50AM  
09:00AM  
06:50AM  
May-31-22 08:00AM  
May-30-22 10:01AM  
May-25-22 12:07PM  
May-24-22 11:13AM  
May-23-22 10:17AM  
05:00AM  
May-19-22 02:16PM  
May-16-22 02:05PM  
May-13-22 01:46PM  
May-12-22 05:24AM  
May-10-22 04:13PM  
02:05PM  
11:41AM  
06:20AM  
May-09-22 07:31PM  
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Murphy NicoleHead of Pharm Ops and TechAug 01Option Exercise0.001,08002,919Aug 03 05:40 PM
Kramer RobinChief Accounting OfficerJul 01Option Exercise0.0025202,092Jul 06 07:33 PM
Izzar RachidHead of Alzheimer's DiseaseJul 01Option Exercise0.0050402,258Jul 06 07:28 PM
Vounatsos MichelChief Executive OfficerFeb 18Option Exercise0.006,191070,007Feb 23 04:21 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerFeb 18Option Exercise0.001,98105,404Feb 23 04:19 PM
Izzar RachidHead of Alzheimer's DiseaseFeb 18Option Exercise0.0059401,929Feb 23 04:16 PM
Kramer RobinChief Accounting OfficerFeb 18Option Exercise0.0039601,854Feb 23 04:18 PM
Murphy NicoleHead of Pharm Ops and TechFeb 18Option Exercise0.0037101,768Feb 23 04:20 PM
Guindo ChirfiHead of Glob Prod Strat & ComFeb 18Option Exercise0.001,98108,243Feb 23 04:15 PM
Gregory GingerEVP, Human ResourcesFeb 18Option Exercise0.001,387011,835Feb 23 04:15 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 18Option Exercise0.001,485045,587Feb 23 04:14 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 12Option Exercise0.002,280045,646Feb 15 04:17 PM
Guindo ChirfiHead of Glob Prod Strat & ComFeb 12Option Exercise0.002,59708,044Feb 15 04:15 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.001,672011,422Feb 15 04:16 PM
Kramer RobinChief Accounting OfficerFeb 12Option Exercise0.0027501,594Feb 15 04:13 PM
Izzar RachidHead of Alzheimer's DiseaseFeb 12Option Exercise0.0035101,457Feb 15 04:14 PM
Murphy NicoleHead of Pharm Ops and TechFeb 12Option Exercise0.0026301,489Feb 15 04:11 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.008,716070,465Feb 15 04:12 PM
Kramer RobinChief Accounting OfficerDec 03Option Exercise223.9233975,9091,210Dec 07 04:09 PM
Izzar RachidHead of Alzheimer's DiseaseDec 02Option Exercise228.5237285,0091,271Dec 06 04:14 PM
MCDONNELL MICHAEL REVP, Chief Financial OfficerSep 01Option Exercise338.246,0052,031,1314,864Sep 03 04:08 PM